Search research articles
Contact Us
Filters
Showing results (161-170 of 231) with videos related to
Page
of 24
Sort By:
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Blood Advances
|
December 11, 2025
Real-world evidence of measurable residual disease assessment in multiple myeloma
Maria Teresa Cedena, Noemi Puig, Bruno Paiva, et al.
Blood Cancer Journal
|
April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Adrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Blood Advances
|
December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
Plos One
|
September 8, 2018
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Marta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
JAMA Oncology
|
August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis
Francesca Gay, Graham Jackson, Laura Rosiñol, et al.
Leukemia
|
August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 231) with videos related to
Sort By:
Page
of 24
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Blood Advances
|
December 11, 2025
Real-world evidence of measurable residual disease assessment in multiple myeloma
Maria Teresa Cedena, Noemi Puig, Bruno Paiva, et al.
Blood Cancer Journal
|
April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Adrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Blood Advances
|
December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
Plos One
|
September 8, 2018
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Marta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
JAMA Oncology
|
August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis
Francesca Gay, Graham Jackson, Laura Rosiñol, et al.
Leukemia
|
August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Page
of 24